These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9668295)

  • 1. Nasal administration of synthetic acetylcholine receptor T epitopes affects the immune response to the acetylcholine receptor and prevents experimental myasthenia gravis.
    Karachunski PI; Ostlie NS; Okita DK; Conti-Fine BM
    Ann N Y Acad Sci; 1998 May; 841():560-4. PubMed ID: 9668295
    [No Abstract]   [Full Text] [Related]  

  • 2. Subcutaneous administration of T-epitope sequences of the acetylcholine receptor prevents experimental myasthenia gravis.
    Karachunski PI; Ostlie NS; Okita DK; Garman R; Conti-Fine BM
    J Neuroimmunol; 1999 Jan; 93(1-2):108-21. PubMed ID: 10378874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of experimental myasthenia gravis by nasal administration of synthetic acetylcholine receptor T epitope sequences.
    Karachunski PI; Ostlie NS; Okita DK; Conti-Fine BM
    J Clin Invest; 1997 Dec; 100(12):3027-35. PubMed ID: 9399949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization of bm12 mice with high doses of acetylcholine receptor overcomes their resistance to experimental autoimmune myasthenia gravis.
    Karachunski PI; Ostlie NS; Lei S; Okita DK; Lindstrom JM; Conti-Fine BM
    Ann N Y Acad Sci; 1998 May; 841():555-9. PubMed ID: 9668294
    [No Abstract]   [Full Text] [Related]  

  • 5. Antigen-specific modulation of experimental myasthenia gravis: nasal tolerization with recombinant fragments of the human acetylcholine receptor alpha-subunit.
    Barchan D; Souroujon MC; Im SH; Antozzi C; Fuchs S
    Proc Natl Acad Sci U S A; 1999 Jul; 96(14):8086-91. PubMed ID: 10393952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of experimental autoimmune myasthenia gravis by recombinant fragments of the human acetylcholine receptor.
    Souroujon MC; Barchan D; Fuchs S
    Ann N Y Acad Sci; 1998 May; 841():572-5. PubMed ID: 9668298
    [No Abstract]   [Full Text] [Related]  

  • 7. Interleukin-4 deficiency facilitates development of experimental myasthenia gravis and precludes its prevention by nasal administration of CD4+ epitope sequences of the acetylcholine receptor.
    Karachunski PI; Ostlie NS; Okita DK; Conti-Fine BM
    J Neuroimmunol; 1999 Mar; 95(1-2):73-84. PubMed ID: 10229117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive protection from experimental myasthenia gravis with T cells from mice treated nasally with acetylcholine receptor epitopes.
    Monfardini C; Milani M; Ostlie N; Wang W; Karachunski PI; Okita DK; Lindstrom J; Conti-Fine BM
    J Neuroimmunol; 2002 Feb; 123(1-2):123-34. PubMed ID: 11880157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T cells from normal and myasthenic individuals recognize the human acetylcholine receptor: heterogeneity of antigenic sites on the alpha-subunit.
    Melms A; Malcherek G; Gern U; Wiethölter H; Müller CA; Schoepfer R; Lindstrom J
    Ann Neurol; 1992 Mar; 31(3):311-8. PubMed ID: 1379027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T helper function of CD4+ cells specific for defined epitopes on the acetylcholine receptor in congenic mouse strains.
    Bellone M; Ostlie N; Lei S; Manfredi AA; Conti-Tronconi BM
    J Autoimmun; 1992 Feb; 5(1):27-46. PubMed ID: 1373061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes.
    Paas-Rozner M; Sela M; Mozes E
    Proc Natl Acad Sci U S A; 2001 Oct; 98(22):12642-7. PubMed ID: 11606745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fas/Fas ligand pathway, apoptosis, and clonal anergy involved in systemic acetylcholine receptor T cell epitope tolerance.
    Deng C; Goluszko E; Christadoss P
    J Immunol; 2001 Mar; 166(5):3458-67. PubMed ID: 11207304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of experimental autoimmune myasthenia gravis by manipulation of the immune network with a complementary peptide for the acetylcholine receptor.
    Araga S; LeBoeuf RD; Blalock JE
    Proc Natl Acad Sci U S A; 1993 Sep; 90(18):8747-51. PubMed ID: 8378359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Residues within the alpha subunit sequence 304-322 of muscle acetylcholine receptor forming autoimmune CD4+ epitopes in BALB/c mice.
    Karachunski PI; Ostlie N; Conti-Tronconi BM; Bellone M
    Immunology; 1994 May; 82(1):22-7. PubMed ID: 7519170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD4+ epitope spreading and differential T cell recognition of muscle acetylcholine receptor subunits in myasthenia gravis.
    Wang ZY; Okita DK; Howard JF; Conti-Fine BM
    Ann N Y Acad Sci; 1998 May; 841():334-7. PubMed ID: 9668253
    [No Abstract]   [Full Text] [Related]  

  • 16. Suppression of experimental autoimmune myasthenia gravis by epitope-specific neonatal tolerance.
    Christadoss P; Shenoy M; Oshima M; Atassi MZ
    Adv Exp Med Biol; 1994; 347():65-75. PubMed ID: 7976734
    [No Abstract]   [Full Text] [Related]  

  • 17. A 17-Mer self-peptide of acetylcholine receptor binds to B cell MHC class II, activates helper T cells, and stimulates autoantibody production and electrophysiologic signs of myasthenia gravis.
    Yoshikawa H; Lambert EH; Walser-Kuntz DR; Yasukawa Y; McCormick DJ; Lennon VA
    J Immunol; 1997 Aug; 159(3):1570-7. PubMed ID: 9233656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosynthetic and synthetic AChR sequences to study T cells in myasthenia gravis.
    Diethelm-Okita B; Wells G; Kuryatov A; Okita D; Howard J; Lindstrom J; Conti-Fine BM
    Ann N Y Acad Sci; 1998 May; 841():320-3. PubMed ID: 9668250
    [No Abstract]   [Full Text] [Related]  

  • 19. Epitopes on the beta subunit of human muscle acetylcholine receptor recognized by CD4+ cells of myasthenia gravis patients and healthy subjects.
    Moiola L; Karachunski P; Protti MP; Howard JF; Conti-Tronconi BM
    J Clin Invest; 1994 Mar; 93(3):1020-8. PubMed ID: 7510715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specificity of the T cell immune response to acetylcholine receptor in experimental autoimmune myasthenia gravis. Response to subunits and synthetic peptides.
    Fujii Y; Lindstrom J
    J Immunol; 1988 Mar; 140(6):1830-7. PubMed ID: 2450133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.